{"title":"Forma Therapeutics和勃林格殷格翰合作靶向肿瘤相关蛋白-蛋白相互作用","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1677","DOIUrl":null,"url":null,"abstract":"Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I2.1677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I2.1677\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I2.1677","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Forma Therapeutics与勃林格殷格翰公司达成了一项为期4年的抗癌药物开发协议，该协议潜在价值高达8.15亿美元，旨在开发针对肿瘤相关蛋白质-蛋白质相互作用的小分子疗法。通过这笔交易，勃林格殷格翰将加入Forma的大型制药合作伙伴名单，其中包括罗氏、卫材和诺华。
Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions
Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
